Affiliation:
1. School of Biomedical Engineering Tsinghua University Beijing 100084 China
2. CapitalBiotech Technology Beijing 101111 China
3. State Key Laboratory of Transducer Technology Aerospace Information Research Institute of Chinese Academy of Sciences Beijing 100190 China
4. National Engineering Research Center for Beijing Biochip Technology Beijing 102200 China
Abstract
AbstractHigh‐quality, low‐cost, and rapid detection is essential for the society to reopen the economy during the critical period of transition from Coronavirus Disease 2019 (COVID‐19) pandemic response to pandemic control. In addition to performing sustainable and target‐driven tracking of SARS‐CoV‐2, conducting comprehensive surveillance of variants and multiple respiratory pathogens is also critical due to the frequency of reinfections, mutation immune escape, and the growing prevalence of the cocirculation of multiple viruses. By utilizing a 0.05 cents wax interface, a Stable Interface assisted Multiplex Pathogenesis Locating Estimation in Onepot (SIMPLEone) using nested RPA and CRISPR/Cas12a enzymatic reporting system is successfully developed. This smartphone‐based SIMPLEone system achieves highly sensitive one‐pot detection of SARS‐CoV‐2 and its variants, or multiple respiratory viruses, in 40 min. A total of 89 clinical samples, 14 environmental samples, and 20 cat swab samples are analyzed by SIMPLEone, demonstrating its excellent sensitivity (3–6 copies/reaction for non‐extraction detection of swab and 100–150 copies/mL for RNA extraction‐based assay), accuracy (>97.7%), and specificity (100%). Furthermore, a high percentage (44.2%) of co‐infection cases are detected in SARS‐CoV‐2‐infected patients using SIMPLEone's multiplex detection capability.
Funder
National Key Research and Development Program of China
National Natural Science Foundation of China
Reference42 articles.
1. Diagnostics for COVID-19: moving from pandemic response to control
2. Global partnership to make available 120 million affordable quality COVID‐19 rapid tests for low‐ and middle‐income countries https://www.who.int/news/item/28‐09‐2020‐global‐partnership‐to‐make‐available‐120‐million‐affordable‐quality‐covid‐19‐rapid‐tests‐for‐low‐‐and‐middle‐income‐countries(accessed: September 2020).
3. As Omicron Takes Hold and Other New Variants Arise, COVID-19 Testing Remains the Universally Agreed Tool to Effect Transition From Pandemic to Endemic State
4. Biochips under COVID-19: a new stage of well-grounded development and accelerated translation
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献